ARTICLE | Emerging Company Profile
Wugen: deploying memory NK cells against cancer
And turning allogeneic CAR T cells against T cell malignancies
May 17, 2021 6:08 PM UTC
Wugen is adding a new subset of NK cells to the cell therapy toolkit with its memory NK cell approach, which may lead to high antitumor efficacy without requiring a CAR or other modifications.
The company was formed in 2018 to develop off-the-shelf CAR T cell therapies, but broadened its scope to include memory NK cells after in-licensing the technology from Washington University in St. Louis last year...
BCIQ Company Profiles